The anthracycline antibiotics include daunorubicin, doxorubicin, epirubicin and idarubicin (which are discussed together) and mitoxantrone, which is an anthracycline analog and discussed separately. (nih.gov)
Epirubicin hydrochloride is the 4-epimer of doxorubicin and is a semi-synthetic derivative of daunorubicin. (nih.gov)
This is a post hoc subanalysis of a prospective non-interventional study in 1,197 patients with breast cancer receiving up to 3 cycles of doxorubicin or epirubicin plus cyclophosphamide and NEPA. (karger.com)
INTRODUCTION - The anthracyclines ( doxorubicin [liposomal and unencapsulated], daunorubicin , idarubicin , epirubicin ) and the anthraquinone mitoxantrone (referred to hereafter as "anthracyclines") are chemotherapeutic agents that cause cardiotoxicity. (medilib.ir)
Anthracyclines3
Review Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin. (nih.gov)
Active or dormant cardiovascular disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or concomitant use of other cardiotoxic drugs may increase the risk of cardiac toxicity. (nih.gov)
Secondary acute myelogenous leukemia (AML) has been reported in patients with breast cancer treated with anthracyclines,including epirubicin. (nih.gov)
Chemotherapeutic agents2
Epirubicin should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. (nih.gov)
Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including epirubicin hydrochloride injection, may result in serious or fatal infections ( 5.8 ). (nih.gov)
Acute dose-limiting2
A dose-dependent, reversible leukopenia and/or neutropenia is the predominant manifestation of hematologic toxicity associated with epirubicin hydrochloride injection and represents the most common acute dose-limiting toxicity ( 5.2 ). (nih.gov)
Myelosuppression is the acute dose-limiting toxicity for most nonspecific chemotherapy. (basicmedicalkey.com)
Hydrochloride injection5
These highlights do not include all the information needed to use EPIRUBICIN HYDROCHLORIDE INJECTION safely and effectively. (nih.gov)
Epirubicin Hydrochloride Injection is an anthracycline topoisomerase II inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer ( 1 ). (nih.gov)
The recommended starting dose of epirubicin hydrochloride injection is 100 to 120 mg/m 2 Dosage reductions are possible when given in certain combinations ( 2.1 ). (nih.gov)
Serum total bilirubin and AST levels should be evaluated before and during treatment with epirubicin hydrochloride injection. (nih.gov)
Epirubicin hydrochloride injection may induce hyperuricemia as a consequence of the extensive purine catabolism that accompanies drug-induced rapid lysis of highly chemosensitive neoplastic cells (tumor-lysis syndrome) ( 5.7 ). (nih.gov)
Cytotoxic7
These cytotoxic antibiotics are often grouped together, even though they have diverse mechanisms of action, widely different indications, a range of efficacies and distinctive toxicities. (nih.gov)
Epirubicin Hydrochloride for Injection is an anthracycline cytotoxic agent, intended for intravenous administration. (nih.gov)
Epirubicin is an anthracycline cytotoxic agent. (nih.gov)
Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. (nih.gov)
The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. (nih.gov)
Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. (nih.gov)
As for the FLOT regimen itself, whether 4 cycles are appropriate is still unclear, and the potential toxicity of the combined treatment of three cytotoxic drugs is worrying. (cancerfax.com)
Chemotherapy3
Although favourable response rates (ORR) have been achieved using combination chemotherapy, particularly platinum-etoposide as the most widely used regimen, only a small proportion of patients survive after 5 years. (springer.com)
In the field of medical treatment, perioperative chemotherapy or neoadjuvant chemotherapy has been applied to gastric cancer and adenocarcinoma of the gastroesophageal junction, and neoadjuvant radiochemotherapy is also widely used in esophageal cancer. (cancerfax.com)
The aptamer RA16 adducted with epirubicin (RA16-epirubicin) showed significantly higher toxicity against targeted NCI-H460 cells and low toxicity against non-targeted tumor cells. (nih.gov)
Although human liver tumor cells have reduced metabolic functions as compared to primary human hepatocytes (PHH) they are widely used for pre-screening tests of drug metabolism and toxicity. (cancerindex.org)
Pharmacokinetics1
Epirubicin pharmacokinetics are linear over the dose range of 60 to 150 mg/m 2 and plasma clearance is not affected by the duration of infusion or administration schedule. (nih.gov)
Cardiac2
Cardiac toxicity with Epirubicin Hydrochloride for Injection may occur at lower cumulative doses whether or not cardiac risk factors are present. (nih.gov)
See "Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma", section on 'Cardiac and pulmonary toxicity' . (medilib.ir)
Esophageal cancer1
A study by Fogh et al of induction chemoradiotherapy followed by surgery, a strategy that is widely used in treating esophageal cancer, found that perioperative morbidity and mortality with this approach was not significantly different in patients aged 70 years or older compared with younger patients. (medscape.com)
Significantly1
The rate of RAM discontinuation for ≤ 6M due to anti-VEGF toxicities was significantly higher in the prior BEV treatment group compared with that in the no prior BEV treatment group (18% vs. 6%, P = 0.02). (kindai.ac.jp)
Remission1
In the neoadjuvant study of gastric cancer, the FLOT scheme compared with the ECX (epirubicin + cisplatin + capecitabine) scheme, the pathological complete remission rate is higher. (cancerfax.com)
Adjuvant1
The cumulative risk of developing treatment-related AML or myodysplastic syndrome (MDS), in 7110 patients with breast cancer who received adjuvant treatment with epirubicin-containing regimens, was estimated as 0.27% at 3 years, 0.46% at 5 years, and 0.55% at 8 years. (nih.gov)
Cyclophosphamide1
She was given a TEC regimen (docetaxel 75 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 600 mg/m(2) every 3 weeks) for one cycle but showed no objective response. (pimpathway.com)
Cardiotoxicity1
Compared with widely used monoclonal antibodies, small-molecule TKIs have unique advantages including oral administration and favorable penetration of blood-brain barrier for brain metastatic BC, and reduced cardiotoxicity. (biomedcentral.com)
Intravenous2
Epirubicin (75 mg/m 2 by intravenous bolus) followed by paclitaxel (175 or 200 mg/m 2 by 3-hour intravenous infusion) was administered on day 1 of each cycle of 21 days. (medscape.com)
Pharmacokinetic parameters for epirubicin following 6- to 10-minute, single-dose intravenous infusions of epirubicin at doses of 60 to 150 mg/m 2 in patients with solid tumors are shown in Table 1. (nih.gov)
Vials1
Epirubicin Hydrochloride for Injection is supplied as a sterile, orange-red, lyophilized powder in single-dose vials containing 50 mg or 200 mg of epirubicin hydrochloride. (nih.gov)
Severe2
Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin or months to years after termination of therapy. (nih.gov)
Taxane scheduling influenced the type of severe toxicities. (biomedcentral.com)
Treatment5
Dosage adjustments after the first treatment cycle should be made based on hematologic and nonhematologic toxicities ( 2.2 ). (nih.gov)
Understanding the mechanism of toxicities can lead to more effective prevention and treatment of these toxicities. (basicmedicalkey.com)
Currently, there is no specific antiviral or a widely-approved vaccine for the treatment or protection against EV-A71. (nature.com)
Both BSO - and ATZ - treatment enhanced H2O2 toxicity in three mesothelioma cell lines. (charismaticplanet.com)
BALB/c mouse with CT26 cells implantation was used as a syngeneic in vivo model for evaluation of treatment and toxicity end points. (propoleo.cl)
Vivo1
Furthermore, RA16-epirubicin adduct exhibited in vivo anti-cancer efficacy, with an inhibition rate of 64.38% ± 7.92% when administrated in H460 xenograft mouse model. (nih.gov)
Patients1
Patients with elevated bilirubin or AST may experience slower clearance of drug with an increase in overall toxicity. (nih.gov)
Potentially1
In a potentially curative setting, the thresholds for toxicity are well known and the testing for toxicity is readily available. (medilib.ir)
Effects1
Suppressive effects of ethanolic extracts prepared from propolis group 12 and its main botanical origin (leaf bud of Baccharis dracunculifolia) on transformation of the aryl hydrocarbon receptor (AhR), the initial action of dioxin toxicity, were investigated. (propoleo.cl)
Therapy1
Identification of genetic variations that affect activation and metabolism may permit the development of individualized therapy that optimize effectiveness and minimize toxicity. (basicmedicalkey.com)
Studies1
Aptamers are widely used in numerous biochemical, bioanalytical, and biological studies. (nih.gov)